topic is largely or exclusively about cardiology products, technologies, markets and/or companies
The applications of surgical sealants, glues and wound closure are many and are rapidly multiplying as more credible data is generated on each application and as physicians gain comfort in working with the products in routine clinical practice.
Below is a sample of surgical sealants, glues and wound closure applications by clinical area:
Source: MedMarket Diligence, LLC; [...]
There are countless disorders, diseases, trauma and other conditions of the human body that can be addressed, in principle, by cellular and tissue-based solutions. These may be due to damage to cells and tissues, such as in burn wounds, skin ulcers, bone fractures and defects and similar conditions in which cell/tissue structure (e.g., skin, [...]
The global market for coronary stents is estimated to be in excess of $7 billion and projected to be growing at 6% per year. With the average age of citizens in developed countries increasing, there is an increased need to provide medical care to the average citizen. As such, an aging population translates into increasing [...]
In the medical technology arena, the markets that draw the most attention (i.e., investment) are those that have historically had the biggest successes (i.e., revenues) due to their ability to have big impact on clinical outcomes.
Therefore, a clinical field beginning to draw much "attention" is in applications of cell therapy and tissue engineering for a [...]
The use of autologous, allogeneic and xenogeneic cells and tissues, the use of biomaterials, cell scaffolding and other approaches to tissue repair and regeneration has become part of arsenal of a number of clinical specialties, with high caseload and market revenue in these areas. In particular, orthopedics and skin applications are well established. And, while [...]
The advances in the understanding and management of vascular — and cardiovascular — diseases over the past 50 years now empower cardiologists and other specialists with many options to achieve target outcomes. A succinct chapter, ”Cell Therapy for Cardiovascular Disease” in the book, “Advances in Vascular Medicine”, highlights cell therapy’s growing role:
Advances in diagnosis and [...]
Our research into the products, technologies, companies and markets for tissue engineering and cell therapy has revealed that the 2009 market was at $6.9 billion. The market has grown dramatically, in commercialized products and company activity, over the past few years and is on an accelerated growth rate as technology hurdles are overcome and clinical [...]
As a follow-up to the Feb. 2 post regarding the settlement of patent disputes between J&J and Boston Scientific, a big driver of that settlement is indeed the level of competitiveness that has come to characterize the coronary stent market. The situation in 2010 is a far cry from the situation in 2003/2004, when the [...]
With Boston Scientific agreeing to settle three outstanding patent suits with Johnson & Johnson’s Cordis division regarding coronary stents for $1.725 billion, the two companies put behind a seven-year fight over the high value market.
Both companies hope to take advantage of the opportunity to move on, with Boston Scientific looking to minimize risk in the [...]
FDA Approves For Permanent Treatment Of Advanced Heart Failure Assist Device Pioneered By Texas Heart Institute At St. Luke’s Episcopal Hospital. See Link
Although designed as a bridge-to-transplant device, the HeartMate II has proven itself sufficiently in trials to warrant its approval as a permanent device. Designed by the Texas Heart Institute, the continuous flow left ventricular [...]
Contact:
